ABT:NYE-Abbott Laboratories (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 106.66

Change

+0.96 (+0.91)%

Market Cap

USD 194.08B

Volume

4.28M

Average Target Price

USD 106.43 (-0.21%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MDT Medtronic plc

+0.32 (+0.30%)

USD144.49B 32.14 22.39
SYK Stryker Corporation

-4.24 (-1.96%)

USD81.06B 47.93 27.16
BSX Boston Scientific Corporation

-0.52 (-1.29%)

USD57.50B 14.53 57.69
EW Edwards Lifesciences Corporati..

-0.18 (-0.21%)

USD52.15B 70.43 39.48
ZBH Zimmer Biomet Holdings, Inc

-3.14 (-2.15%)

USD30.74B 815.71 37.09
SNN Smith & Nephew plc

-0.49 (-1.20%)

USD17.77B 44.96 22.00
BIO Bio-Rad Laboratories, Inc

-1.66 (-0.32%)

USD15.06B 7.80 5.41
BIO-B Bio-Rad Laboratories, Inc

N/A

USD15.05B 7.44 5.43
PEN Penumbra, Inc

+3.28 (+1.67%)

USD7.08B 692.52 415.41
GMED Globus Medical, Inc

-0.75 (-1.40%)

USD5.23B 63.68 33.35

ETFs Containing ABT

Symbol Name Weight Mer Price(Change) Market Cap
LIFE:CA Evolve Global Healthcare .. 4.93 % 0.45 %

-0.02 (-0.09%)

USD0.01B
SXLV:LSE SPDR S&P U.S. Health Care.. 4.35 % 0.15 %

-0.26 (-0.85%)

USD0.26B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 4.31 % 0.15 %

-0.19 (-0.71%)

USD0.24B
ZPDH:F SPDR S&P U.S. Health Care.. 4.31 % 0.15 %

-0.19 (-0.73%)

USD0.24B
IHCU:LSE iShares S&P 500 Health Ca.. 4.30 % 0.15 %

-3.25 (-0.53%)

USD1.69B
QDVG:F iShares S&P 500 Health Ca.. 4.30 % 0.15 %

-0.05 (-0.75%)

USD1.69B
QDVG:XETRA iShares S&P 500 Health Ca.. 4.30 % 0.15 %

-0.05 (-0.73%)

USD1.69B
XUHC:XETRA Xtrackers MSCI USA Health.. 4.04 % 0.12 %

-0.30 (-0.81%)

USD0.71B
XSHC:LSE Xtrackers MSCI USA Health.. 4.04 % 0.12 %

-18.50 (-0.56%)

USD0.71B
IUHC:LSE iShares S&P 500 Health Ca.. 3.94 % 0.15 %

-0.07 (-0.89%)

USD1.17B
XUHC:LSE Xtrackers (IE) Public Lim.. 3.82 % 0.12 %

-0.39 (-0.89%)

USD0.40B
GDNA Goldman Sachs Human Evolu.. 3.78 % 0.50 %

-0.26 (-0.40%)

USD0.03B
ISUS:LSE iShares MSCI USA Islamic .. 3.47 % 0.50 %

-25.50 (-0.71%)

USD0.07B
LS:CA Middlefield Healthcare & .. 3.30 % 0.85 %

-0.16 (-1.46%)

USD0.08B
WOMN:CA BMO Women In Leadership F.. 3.10 % 0.39 %

N/A

USD0.05B
WHEA:LSE SPDR MSCI World Health Ca.. 2.86 % 0.30 %

-0.29 (-0.60%)

USD0.30B
XDWH:LSE Xtrackers MSCI World Heal.. 2.79 % 0.30 %

-0.25 (-0.60%)

USD0.93B
XDWH:F Xtrackers MSCI World Heal.. 2.73 % 0.30 %

-0.14 (-0.39%)

USD0.93B
XDWH:XETRA Xtrackers MSCI World Heal.. 2.73 % 0.30 %

-0.17 (-0.49%)

USD0.93B
ISDU:LSE iShares MSCI USA Islamic .. 2.71 % 0.50 %

-0.47 (-1.01%)

USD0.08B
TGED:CA TD Active Global Enhanced.. 2.14 % 0.65 %

-0.24 (-1.44%)

USD0.03B
HWF:CA Middlefield Health & .. 0.00 % 0.85 %

N/A

USD0.05B
FHI Federated Hermes, Inc 0.00 % 0.00 %

-0.48 (-2.09%)

N/A
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

-0.23 (-0.58%)

USD0.04B
JKD iShares Morningstar Large.. 0.00 % 0.20 %

-1.63 (-0.83%)

USD0.75B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.21 (-0.33%)

USD0.36B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.09 (+0.79%)

USD2.46M
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

-0.43 (-0.19%)

USD2.33B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

-0.04 (-0.06%)

USD2.17B
CURE Direxion Daily Healthcare.. 0.00 % 1.08 %

-0.73 (-1.15%)

USD0.13B
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

-0.11 (-0.21%)

USD1.91B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

-1.17 (-0.39%)

USD6.60B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.09 (+0.79%)

USD2.46M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

-1.04 (-0.80%)

USD0.10B
ACT AdvisorShares Vice ETF 0.00 % 0.99 %

-0.38 (-1.43%)

USD9.13M
HIG:CA Brompton Global Healthcar.. 0.00 % 0.00 %

-0.09 (-0.98%)

USD0.05B
BSCL Invesco BulletShares 2021.. 0.00 % 0.10 %

+0.01 (+0.05%)

USD1.95B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

-0.03 (-0.13%)

USD0.01B
LIFE aTyr Pharma, Inc 0.00 % 0.00 %

+0.02 (+0.48%)

USD0.04B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

-0.65 (-0.32%)

USD12.45B
XHC:CA iShares Global Healthcare.. 0.00 % 0.63 %

-0.12 (-0.21%)

USD0.37B
XLV Health Care Select Sector.. 0.00 % 0.13 %

-0.42 (-0.40%)

USD23.23B
RWDC Direxion MSCI Defensives .. 0.00 % 0.46 %

-0.11 (-0.23%)

USD7.11M

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.80% 80% B- 89% B+
Dividend Return 1.24% 100% A+ 42% F
Total Return 24.04% 80% B- 90% A-
Trailing 12 Months  
Capital Gain 27.52% 68% D+ 88% B+
Dividend Return 1.67% 86% B 38% F
Total Return 29.20% 68% D+ 88% B+
Trailing 5 Years  
Capital Gain 146.16% 69% D+ 92% A-
Dividend Return 13.43% 100% A+ 47% F
Total Return 159.59% 69% D+ 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 21.69% N/A N/A N/A N/A
Dividend Return 2.17% N/A N/A N/A N/A
Total Return 23.87% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.53% N/A N/A N/A N/A
Risk Adjusted Return 164.30% N/A N/A N/A N/A
Market Capitalization 194.08B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.87 50% F 10% F
Price/Book Ratio 6.06 21% F 13% F
Price / Cash Flow Ratio 31.63 32% F 8% F
EV/EBITDA 27.52 45% F 15% F
Management Effectiveness  
Return on Equity 9.86% 75% C 67% D+
Return on Invested Capital 8.34% 72% C- 64% D
Return on Assets 4.01% 84% B 73% C
Debt to Equity Ratio 53.59% 50% F 58% F
Technical Ratios  
Short Ratio 1.82 64% D 55% F
Short Percent 0.60% 91% A- 88% B+
Beta 0.95 64% D 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.